Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nasopharyngeal Carcinoma 4 Head and Neck Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Uterine Cervical Neoplasms 2 Nasopharyngeal Neoplasms 2 Esophageal Neoplasms 2 Stomach Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms 1 Nasopharyngeal Diseases 1 Colorectal Neoplasms 1 Carcinoma 1

Interventions

Paclitaxel 20 Gemcitabine 16 Dexamethasone 16 Bevacizumab 16 Docetaxel 15 Oxaliplatin 14 Cyclophosphamide 13 Carboplatin 12 Capecitabine 12 Sorafenib 11 Fluorouracil 11 Leucovorin 10 Cisplatin 10 pembrolizumab 9 Pemetrexed 9 Epoetin Alfa 9 venetoclax 8 Prednisone 8 Fentanyl 8 Drug Therapy 8 Doxorubicin 8 atezolizumab 7 Rivaroxaban 7 Rituximab 7 Darbepoetin alfa 7 Anastrozole 7 Panitumumab 6 Ondansetron 6 Morphine 6 Irinotecan 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × nimotuzumab × Clear all

NCT03413579 2021-08-25

CIMAHOPE

El Kendi Pharmaceuticals Manufacturing Company

Phase 3 Completed

Uterine Cervical Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡